Entrada Therapeutics NASDAQ:TRDA reported an insider sale by Chief Financial Officer Wentworth Kory James on April 1, 2026, according to a Form 4 filed with the Securities and Exchange Commission.
Per the filing, Wentworth sold 2,500 shares of common stock at $12.95 per share, producing proceeds of $32,375. Following that disposition, Wentworth directly holds 119010 shares of Entrada Therapeutics common stock.
The transaction was carried out under a pre-established Rule 10b5-1 trading plan that the company says was adopted on March 6, 2025. The sale occurred while TRDA shares were trading close to their 52-week high of $13.66, with the stock up approximately 53% over the prior 12 months.
Market context and analyst notes
Third-party analysis from InvestingPro included in the filing indicates that, at current levels, the stock appears overvalued, even as some sell- and buy-side analysts maintain price targets in the $19 to $21 range. The InvestingPro platform also identifies 14 additional ProTips for TRDA investors.
Clinical development timeline
Separately, Entrada provided an update on its development portfolio, which centers on RNA-based therapeutic programs for neuromuscular and ocular indications. The company said it expects to report data from the first cohort of the ELEVATE-44-201 study, a trial involving patients with Duchenne muscular dystrophy, in the second quarter of 2026. Entrada also plans to disclose data from the first cohort of the ELEVATE-45-201 study in mid-2026.
These planned readouts are cited by the company as part of ongoing efforts to advance its pipeline across neuromuscular and ocular disease areas. Investors and market participants will be watching the upcoming cohorts and the timing of the releases.
What the filing shows
- Insider: Wentworth Kory James, Chief Financial Officer
- Shares sold: 2,500
- Sale date: April 1, 2026
- Price per share: $12.95
- Total transaction value: $32,375
- Post-sale direct ownership: 119010 shares
- Trading plan: Rule 10b5-1 adopted March 6, 2025
Entrada’s projected clinical milestones for the ELEVATE-44-201 and ELEVATE-45-201 cohorts remain scheduled for the second quarter and mid-2026, respectively, according to the company update referenced in the filing.